CME-Directory

Mayo Clinic Hematology/Oncology Reviews is a comprehensive postgraduate course designed to provide the busy practicing hematologist/oncologist with practical new developments. Didactic presentations will be case-based. Attendees will leave with up-to-date, practical information which will have immediate clinical application.

Mayo Clinic Hematology/Oncology Reviews is a comprehensive postgraduate course designed to provide the busy practicing hematologist/oncologist with practical new developments. Didactic presentations will be case-based. Attendees will leave with up-to-date, practical information which will have immediate clinical application.

The Merging and Redirecting Traffic: Exploiting the Biology of Renal Cell Carcinoma symposium is designed to update physicians on the latest information regarding the optimal treatment of patients with renal cell carcinoma using targeted agents and how to integrate this information into everyday practice. The symposium focuses on the current standard of care for patients with newly diagnosed disease, the optimal sequence of targeted agents in individualized therapy, the potential role of combining therapeutics in maximizing patient benefit, and emerging therapeutic agents and how they will be integrated into the treatment algorithm. This symposium will also address current options for the treatment of advanced disease following progression on previous targeted agents. This educational program is directed toward medical, surgical, and radiation oncologists with an interest in the treatment of kidney cancer. Fellows, oncology physician assistants, oncology nurses, and research nurses with an interest in the treatment of patients with kidney cancer are also invited to attend.

The Ninth International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic standards for all aspects of the treatment of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and novel therapeutic agents. Interactive panel discussions and case-based scenarios will provide context for the interpretation of presented data from clinical trials. Faculty recommendations and interactive tumor board–style discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to integrate the latest advances in the treatment of genitourinary malignancies into their daily practice as well as discuss future directions in research and clinical trials. This educational program is directed toward medical, surgical, and radiation oncologists; urologists; internal medicine and primary care physicians; and basic research investigators. Fellows, oncology nurses, physician assistants, and pharmacists interested in the treatment and management of patients with genitourinary malignancies are also invited to attend.

The Ninth International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic standards for all aspects of the treatment of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and novel therapeutic agents. Interactive panel discussions and case-based scenarios will provide context for the interpretation of presented data from clinical trials. Faculty recommendations and interactive tumor board–style discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to integrate the latest advances in the treatment of genitourinary malignancies into their daily practice as well as discuss future directions in research and clinical trials. This educational program is directed toward medical, surgical, and radiation oncologists; urologists; internal medicine and primary care physicians; and basic research investigators. Fellows, oncology nurses, physician assistants, and pharmacists interested in the treatment and management of patients with genitourinary malignancies are also invited to attend.

Hello, I am contacting you today in hopes you will be able to forward this important educational information on to your Fellows, MD’s and Nurses regarding Physicians' Education Resource’s up coming cancer meeting on August 20 -22, 2010. For more information about this meeting and other up coming meetings please go to our website at www.cancerlearning.com. Thank you A unique opportunity for medical oncologists, translational researchers (MDs and PhDs), and drug developers from academia and industry to learn from and interact with international leaders in the field of novel therapeutic and drug discovery platforms and to obtain a preview of new agents in development for the next generation of cancer therapy. Topics to be included: • Concise overviews of the biology underpinning the development of new targeted agents • Expert analysis of therapeutic agents targeting intracellular signaling, cell surface receptors, and the tumor microenvironment • Discussion of novel therapeutic discovery platforms • Clinically oriented lectures to provide physicians with practical applications for improved patient care

CME-Certified Congress The Ninth International Congress on the Future of Breast Cancer is an international educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be discussed and controversial issues debated in panel discussions. Strategies for optimizing the use of endocrine therapy, conventional chemotherapy, and targeted therapies will be presented. Evolving diagnostic approaches to identify the driving mutations or pathways in breast cancers will be thoroughly discussed along with the therapies targeting those mutations. Controversial issues in the surgical and radiotherapeutic management of breast cancer will also be discussed and debated. The format will include didactic sessions from thought leaders, question-and-answer panel discussions, and ample time for participant interaction with faculty.

Oncology Practice Reviews *Part of a PER conference series [ View Series Overview ] George R. Brown Convention Center Houston, TX March 12-13, 2010 Conference Overview CME Symposium This activity is presented by Physicians’ Education Resource in conjunction with The University of Texas M. D. Anderson Cancer Center. Oncology Practice Reviews is a 2-day symposium designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including breast cancer, genitourinary malignancies, lymphoma, gastrointestinal malignancies, lung cancer, multiple myeloma, myelodysplastic syndromes, leukemia, and chronic lymphocytic leukemia, in addition to other special topics unique to each meeting location. To enhance learning, participants will be engaged in solving “real-world” problems through practical, interactive, case-based presentations. * Industry-led lectures and exhibits will be conducted as optional learning opportunities in conjunction with this event. These optional activities are not certified for CME credit and are not planned or sanctioned by PER. Product and Research & Development Theaters will provide promotional product-specific information on available agents and products in development, respectively. Educational Methods Lectures, Questions-and-Answers, Case-Based Panel Discussions, Audience Response System Target Audience This activity is directed toward medical oncologists and hematologists practicing in the community or academic setting who are interested in recent advances in the treatment of solid tumors and hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to attend. Learning Objectives At the conclusion of this symposium, you should be able to: • Assess the efficacy and safety of targeted agents in the management of patients with solid tumors and hematologic malignancies • Summarize new data that might influence current treatment and monitoring strategies for patients with newly diagnosed leukemia, lymphoma, and myeloma • Interpret the significance of clinical and molecular characteristics in choosing therapies for patients with solid tumors • Identify results of recent clinical trials that are currently applicable to the management of patients with solid tumors and hematologic malignancies The University of Texas M. D. Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. M. D. Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. M. D. Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth. Photographing, audio taping, and videotaping are prohibited. Please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chair(s) for consideration

Oncology Practice Reviews *Part of a PER conference series [ View Series Overview ] JW Marriott Hotel Los Angeles at L.A. LIVE Los Angeles, CA March 26-27, 2010 Conference Overview CME-Certified Symposium This activity is presented by Physicians’ Education Resource in conjunction with the Keck School of Medicine of the University of Southern California. Oncology Practice Reviews is a 2-day symposium designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including breast cancer, genitourinary malignancies, lymphoma, gastrointestinal malignancies, lung cancer, multiple myeloma, myelodysplastic syndromes, leukemia, and chronic lymphocytic leukemia, in addition to other special topics unique to each meeting location. To enhance learning, participants will be engaged in solving “real-world” problems through practical, interactive, case-based presentations. * Industry-led lectures and exhibits will be conducted as optional learning opportunities in conjunction with this event. These optional activities are not certified for CME credit and are not planned or sanctioned by PER. Product and Research & Development Theaters will provide promotional product-specific information on available agents and products in development, respectively. Target Audience This educational program is directed toward medical oncologists and hematologists practicing in the community or academic setting who are interested in recent advances in the treatment of solid tumors and hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to attend. Learning Objectives At the conclusion of this symposium, you should be able to: • Assess the efficacy and safety of targeted agents in the management of patients with solid tumors and hematologic malignancies • Identify results of recent clinical trials that are currently applicable to the management of patients with solid tumors and hematologic malignancies Continuing Education Information Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians’ Education Resource designates this educational activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME. Registered Nurses: The California Board of Registered Nursing accepts AMA PRA Category 1 Credits™ toward license renewal. On the BRN license renewal form, report the number of hours you attended (up to 12.25 hours of credit) and fill in “CME Category 1” for the provider number. California AB 1195: This activity complies with California Assembly Bill 1195, signed November 2005, requiring continuing medical education courses with patient care components to include curricula in the subject of cultural and linguistic competency. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area.

Oncology Practice Reviews *Part of a PER conference series [ View Series Overview ] The Westin Tyson’s Corner Washington, DC April 16-17, 2010 Summary and Purpose CME-Certified Symposium This activity is presented by Physicians’ Education Resource in conjunction with Duke Oncology Network. Oncology Practice Reviews is a 2-day symposium designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including breast cancer, genitourinary malignancies, lymphoma, gastrointestinal malignancies, lung cancer, multiple myeloma, myelodysplastic syndromes, leukemia, and chronic lymphocytic leukemia, in addition to other special topics unique to each meeting location. To enhance learning, participants will be engaged in solving “real-world” problems through practical, interactive, case-based presentations. Product Theaters Industry-led lectures and exhibits will be conducted in conjunction with this event to provide promotional product-specific information on available agents and products in development, respectively. These optional activities are not certified for CME credit and are not planned or sanctioned by PER. Target Audience This educational program is directed toward medical oncologists and hematologists practicing in the community or academic setting who are interested in recent advances in the treatment of solid tumors and hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to attend. Learning Objectives At the conclusion of this symposium, you should be able to: • Assess the efficacy and safety of targeted agents in the management of patients with solid tumors and hematologic malignancies • Identify results of recent clinical trials that are currently applicable to the management of patients with solid tumors and hematologic malignancies Continuing Education Information Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians’ Education Resource designates this educational activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

A 2-day symposium designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including breast cancer, genitourinary malignancies, lymphoma, gastrointestinal malignancies, lung cancer, multiple myeloma, myelodysplastic syndromes, leukemia, and chronic lymphocytic leukemia, in addition to other special topics unique to each meeting location. To enhance learning, participants will be engaged in solving “real-world” problems through practical, interactive, case-based presentations. Product Theaters Industry-led lectures and exhibits will be conducted in conjunction with this event to provide promotional product-specific information on available agents and products in development, respectively. These optional activities are not certified for CME credit and are not planned or sanctioned by PER.

Please join us for a CME dinner program on November 13, 2008 in Beverly Hills presented by Peter McLaughlin, MD and Lauren Pinter-Brown, MD. Learning Objectives: At the conclusion of the program, participants will be able to provide an overview of current treatment strategies for indolent NHL. 1. Understand the use of rituximab in the treatment of indolent NHL. 2. Explain the benefits of combination GM-CSF/rituximab therapy. 3. Review tumor-specific Id-KLH vaccines and their use in combination with GM-CSF. 4. Recognize the benefits of adjunctive GM-CSF in therapies for indolent NHL.

Chairs: Martin J. van den Bent, MD, PhD and W.K. Alfred Yung, MD Abstract Deadline: 1 March 2006

This educational activity is specifically designed for medical and surgical oncologists, dermatologists, researchers and other physicians, physicians-in-training and other healthcare professionals interested in and/or involved in the care of patients with melanoma and its consequences. Chairs: Arnold Monto, MD and John Oxford, MD

The Practical Updates in Oncology symposium brings together academic and community physicians for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, followed by new clinical trial designs and case-based panel discussions on practical disease management. The Ethics session will cover key issues in patient communication and shared decision making. This meeting presents an opportunity for continuous dialogue and interaction between academic thought leaders and community oncologists. The presentation “Ethics Lecture: Patient Communication and Shared Decision Making” has been designated by Physicians’ Education Resource for 1 hour education in medical ethics and/or professional responsibility. This educational program is directed toward medical, radiation, and surgical oncologists with an interest in recent advances in the treatment of solid tumors as well as hematologic malignancies. Fellows, oncology nurses, oncology physician assistants, and pharmacists are also invited to attend.

Please join us for a CME dinner program on November 5, 2008 in Philadelphia presented by John Kirkwood, MD and Michael Morse, MD. Learning Objectives: At the conclusion of the program, participants will be able to: 1. Understand the pathophysiology of melanoma. 2. Review current treatments for the different stages of melanoma. 3. Explain the utility of colony-stimulating factor in the management of melanoma. 4. Understand the current clinical data regarding use of colony-stimulating factor in the treatment of melanoma.

Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer. In order to advance patient care, the School of Breast Oncology was developed. This curriculum-based program focuses exclusively on breast cancer clinical management. This intensive 4-day interactive educational course will provide a comprehensive review of the existing data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment. The curriculum will be evidence based, summarizing the existing data for each topic and applying these data to patient cases. Target Audience This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer. Learning Objectives At the conclusion of this school, you should be able to: Discuss breast carcinogenesis and the impact of germline mutations on patient management Explain the clinical utility and limitations of sentinel lymph node biopsy Integrate current staging guidelines into clinical decision making regarding local and systemic therapies Discuss advances in breast cancer imaging and early detection, including mammography, ultrasound, MRI, and PET scanning Integrate prognostic and predictive factors for breast cancer into patient management decisions and assess the optimal means of HER2 and hormone receptor expression analysis Assess optimal radiation therapy strategies for treatment of patients with DCIS, early-stage, and locally advanced breast cancer Critically analyze the data guiding the choice of adjuvant chemotherapies, endocrine therapies, or targeted agents for patients with low- and high-risk breast cancer and for elderly patients Evaluate the evidence guiding treatment recommendations for the management of patients with hormone-dependent and hormone-independent metastatic breast cancer Evaluate organ-specific therapeutic interventions for patients with metastatic disease to the CNS and skeleton Integrate palliative care strategies into treatment algorithms for metastatic disease List novel chemotherapies and targeted agents currently under evaluation for the treatment of advanced and early-stage breast cancer Describe current and emerging strategies for ameliorating or eliminating therapy-associated adverse events Assess the evidence supporting an emphasis on quality of life and rehabilitation during and after breast cancer treatment Refer appropriate patients to promising clinical trials ...

The primary objective of this course is to bring together clinicians and leading experts in diverse areas of hematology and oncology, affording them an intimate environment in which to discuss new clinical developments and significant advances.

The Seventh Annual Current Trends in Genitourinary Malignancies regional symposium is designed to provide state-of-the-art information on the clinical management of bladder, kidney, prostate, and testicular cancers. Current evidence-based treatment approaches to all stages of bladder cancer, including surgery, radiation therapy, neoadjuvant therapy, and systemic chemotherapies and targeted therapies, will be discussed with an emphasis on practical clinical context to facilitate integration into practice. The benefits and risks of alternative therapeutic strategies for early-stage renal cell carcinoma will be addressed, along with expert insights on relevant data for the selection of appropriate therapy for individual patients with advanced clear cell and non–clear cell renal cell carcinoma in multiple settings. A debate will highlight current evidence concerning the management of early-stage testicular cancer using alternative therapeutic approaches. Participants will review recent data on active surveillance, adjuvant therapy, immunotherapy, and emerging systemic therapies for the clinical management of patients with all stages of prostate cancer. In addition, the symposium will include updates on relevant ongoing clinical trials evaluating new therapeutic regimens for the treatment of genitourinary malignancies. This interactive symposium will include didactic sessions, case-based learning, and panel discussions with leading faculty who will offer their opinions regarding the clinical challenges that practicing physicians face today.

Now in its seventh year, the 2010 Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia symposium is designed to address gaps in knowledge for practicing medical oncologists and hematologists and will present current standards, practical issues, and controversies in the management of myeloma, lymphoma, and leukemia, and other hematologic malignancies. In addition, controversies in the management of these diseases will be discussed in the form of didactic lectures with panel discussions and case-based discussions with interactive audience response system capabilities. Emphasis will be placed on discussion of current issues in the treatment of hematologic malignancies in a practical context, focusing on conveying key findings from recent clinical studies that will most directly impact physician practice. Case discussions and patient management will be highlighted, providing a forum to discuss and debate the practical applicability of evolving clinical trial findings.

The Sixth Annual New York Lung Cancer Symposium offers medical, surgical, and radiation oncologists and other health care professionals the opportunity to learn about the latest developments in lung cancer treatments, including findings presented at recent major oncology conferences. Both didactic presentations and interactive case discussions will foster the integration of evidence-based patient care into everyday community practice.

Presented by Physicians’ Education Resource in conjunction with the Virginia G. Piper Cancer Center at Scottsdale Healthcare. Treatment for the various hematologic malignancies is rapidly evolving with advances such as new chemoimmunotherapeutic regimens, novel tyrosine kinase inhibitors, and improved induction regimens. As these next-generation agents and approaches are associated with improved survival and/or reduced toxicity compared to earlier regimens, it is critical that physicians stay up to date with these therapeutic advances to provide their patients with the best possible care. The Sixth Annual Symposium on Controversies and Clinical Challenges In Lymphoma, Myeloma, and Leukemia is designed to address these gaps in knowledge for practicing medical oncologists and hematologists and will transmit recent advances and new data on the treatment and management of lymphoma, myeloma, leukemias, and other hematological malignancies. Additionally, controversies in management of these diseases will be discussed both in the form of didactic lectures with panel discussions, as well as case-based discussions with interactive response system capabilities. Emphasis will be placed on discussion of current issues in the treatment of hematologic malignancies in a practical context, focusing on conveying the key findings from recent meetings, which will most directly impact optimal physician practice. Case discussions and patient management will be highlighted, providing a forum to discuss and debate the controversies and practical applicability of the evolving clinical trial findings.

The Sixth International Symposium on Ovarian Cancer and Other Gynecologic Malignancies will provide participants with cutting-edge information on the screening, diagnosis, and treatment of these diseases. This symposium will focus on clinical and translational research in the areas of ovarian, uterine, and endometrial cancers, discussing not only standards of care and current guidelines but also the most promising novel chemotherapeutics and targeted agents. Controversies in combined modality approaches to and chemotherapeutic management of ovarian cancers as well as issues revolving around staging and treatment strategies for endometrial cancers will be debated. Didactic lectures, case-based discussions, and debates will provide participants with ample opportunities to learn from and interact with key opinion leaders in the field. This educational program is directed toward medical, gynecologic, surgical, and radiation oncologists. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of ovarian cancer and other gynecologic malignancies are also invited to attend.

This two-day workshop will address the need to integrate quality improvement and safety into medical education. Designed for health profession educators, this workshop will disseminate the knowledge and tools necessary to successfully implement QI and safety education in undergraduate medical education (UME), graduate medical education (GME), continuing medical education (CME), and allied health schools.

The Tenth International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic strategies for the treatment of all stages of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and new therapeutic agents. Interactive panel discussions and case-based vignettes will provide practical clinical context for the interpretation of the presented trial data. Faculty recommendations and an interactive tumor board discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to apply the latest advances in the treatment of genitourinary malignancies to their daily practice and discuss future directions in research and clinical trials.